

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10523655	
	Filing Date		2005-02-04	
	First Named Inventor	ESCHER, Alan P.		
	Art Unit	1633		
	Examiner Name	To be assigned		
Attorney Docket Number		14102-1US		

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.			T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10523655
Filing Date	2005-02-04
First Named Inventor	ESCHER, Alan P.
Art Unit	1633
Examiner Name	To be assigned
Attorney Docket Number	14102-1US

1	KLINMAN, D. et al., "Use of CpG oligodeoxynucleotides as immune adjuvants," Imm. Rev., 2004, Vol. 199, pp. 201-216	<input type="checkbox"/>
2	KRIEG, Arthur M., "The role of CpG motifs in innate immunity," Curr. Opin. Immun., 2000, Vol. 12, pp. 35-43	<input type="checkbox"/>
3	LI, Alice et al., "Co-delivery of pro-apoptotic BAX with a DNA vaccine recruits dendritic cells and promotes efficacy of autoimmune diabetes prevention in mice," Vaccine 22 (2004) pp. 1751-1763	<input type="checkbox"/>
4	LI, Alice et al., "Pro-apoptotic DNA vaccination ameliorates new onset of autoimmune diabetes in NOD mice and induces foxp3+ regulatory T cells in vitro," Vaccine 24 (2006) pp. 5036-5046	<input type="checkbox"/>
5	SCHEULE, R. K., "The role of CpG motifs in immunostimulation and gene therapy," Adv. Drug Delivery Rev., 2000, Vol. 44, pp. 119-134	<input type="checkbox"/>
6	International Search Report and Written Opinion issued in related International Patent Application No. PCT/US06/17763 on September 20, 2007	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.